This page shows the publications co-authored by Robert Langer and Oliver Jonas.
Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities. Clin Cancer Res. 2016 Dec 15; 22(24):6031-6038.
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med. 2015 Apr 22; 7(284):284ra57.
In vivo detection of drug-induced apoptosis in tumors using Raman spectroscopy. Analyst. 2018 Oct 08; 143(20):4836-4839.
First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. J Biomed Nanotechnol. 2016 Jun; 12(6):1297-302.
Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 2017 05 31; 6.
Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors. Nat Med. 2017 Feb; 23(2):235-241.
Integrated genetic and pharmacologic interrogation of rare cancers. Nat Commun. 2016 06 22; 7:11987.
Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression. Cancer Discov. 2016 05; 6(5):516-31.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.